Antibodies and Reagents for Cancer Research
Cancer is the leading cause of death worldwide, and cancer research is crucial for better targeted therapies, improved diagnostic methods, and deeper understanding of the pathways involved in tumor pathogenesis. To empower cancer researchers, Vector Laboratories has curated antibodies targeting key antigens and reagents enabling streamlined workflows for cancer research.
Cancer Research Application Workflows
Successful workflows in cancer research begin with high-quality reagents and antibodies. With nearly 50 years of experience producing and providing scientists with the best tools for the job, the Vector catalog offers highly cited antibodies and reliable reagents designed to streamline workflows. Learn more about our end-to-end application workflow solutions for immunohistochemistry (IHC) and immunofluorescence (IF).
Cancer Research Solutions
Vector Laboratories is committed to providing high-quality research antibodies and reagents for cancer research that support a variety of applications and provide reliable performance. The following Vector products empower researchers to explore cancer therapeutic development, diagnostics, and research.
Primary Antibodies for Cancer Research
The specificity and sensitivity of antibodies can unlock discoveries in cancer research, but not all antibodies are created equal. We produce best-in-class antibodies against a variety of targets relevant to cancer research.
Recombinant Antibodies
Our Absolute Antibody brand specializes in recombinant antibodies, which ensure batch-to-batch reproducibility and enable new antibody engineering opportunities.
Our immunotherapy antibodies target clinically relevant antigens and include VivopureX™ mouse-anti-mouse antibodies with tailored effector function for therapeutic modulation and reduced immunogenicity in vivo.
Research-grade biosimilars are identical to therapeutic-grade biologics at a fraction of the cost and are available in different constant domains.
Additionally, we offer tumor marker antibodies built to bind specifically to tumor associated antigens.
Our LSBio brand specializes in IHC validation, offering more than 15,000 antibodies validated for immunohistochemistry with a focus on cancer biomarkers.
IHC-Plus™ antibodies have been rigorously tested to deliver optimal performance in immunohistochemistry (IHC) studies on formalin-fixed paraffin-embedded (FFPE) human tissues.
PathPlus™ antibodies represent the highest quality reagents available for research pathology applications, shown to be the best performing reagents for immunohistochemical detection of high-value cancer targets.
Our Everest brand specializes in anti-peptide and antigen affinity purified goat polyclonal antibodies, especially useful in applications that require high affinity antibodies at cost-effective prices.
The catalog contains thousands of goat antibodies against a broad range of human, mouse, and rat proteins of biomedical interest, like IGF1, FOXP3/SCURFIN, and CEP290. Many of Everest’s antibodies include validation data in ELISA and western blot (WB) applications.
These highly-cited antibodies from the Vector portfolio target antigens of interest in cancer research.
IHC-plus™ Polyclonal Rabbit anti-Human p16INK4a Antibody
Our high-quality antibodies and reagents support cancer research across multiple applications, enabling the study of key biomarkers and pathways in breast, colorectal, lung, and prostate cancer. Explore how our products advance research in these featured cancer types.
Breast Cancer
Colorectal Cancer
Lung Cancer
Prostate Cancer
For more information on how Vector’s portfolio of products supports cancer research, explore the following resources.
IHC Markers:
Anti-Tumor Efficacy of Syngeneic Engineered Anti-PD-1 vs. Original Antibody
This research poster demonstrates that a recombinant, species-switched version of an anti-PD-1 antibody shows greater therapeutic efficacy in vivo than the original version.
Learn more about how antibody therapeutics work for cancer and other diseases, including how antibody format affects treatment efficacy.
These articles cover proteins of interest in cancer research and therapeutic development, including how recombinant antibodies advance our understanding of these targets.
